63 related articles for article (PubMed ID: 34252268)
1. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
[TBL] [Abstract][Full Text] [Related]
2. Bioactive components and mechanisms of Pu-erh tea in improving levodopa metabolism in rats through COMT inhibition.
Zhou Z; Li Y; Wang F; Zhu G; Qi S; Wang H; Ma Y; Zhu R; Zheng Y; Ge G; Wang P
Food Funct; 2024 May; 15(10):5287-5299. PubMed ID: 38639730
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase and monoamine oxidase B inhibitory activities of Australian bee pollen.
Watanabe C; Yanagihara A; Miyata R; Mitsui T; Honda C; Fujinami D; Kumazawa S
Biosci Biotechnol Biochem; 2024 May; 88(6):665-670. PubMed ID: 38561637
[TBL] [Abstract][Full Text] [Related]
4. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.
Ma Z; Liu H; Wu B
Br J Clin Pharmacol; 2014 Mar; 77(3):410-20. PubMed ID: 23713800
[TBL] [Abstract][Full Text] [Related]
5. Development of a PC12 Cell Based Assay for Screening Catechol-
Zhang G; Buchler IP; DePasquale M; Wormald M; Liao G; Wei H; Barrow JC; Carr GV
ACS Chem Neurosci; 2019 Oct; 10(10):4221-4226. PubMed ID: 31491076
[TBL] [Abstract][Full Text] [Related]
6. Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives.
Pinto M; Silva TB; Sardão VA; Simões R; Albuquerque B; Oliveira PJ; Valente MJ; Remião F; Soares-da-Silva P; Fernandes C; Borges F
ACS Pharmacol Transl Sci; 2024 May; 7(5):1637-1649. PubMed ID: 38751615
[TBL] [Abstract][Full Text] [Related]
7. Computational Investigation of the Interplay of Substrate Positioning and Reactivity in Catechol O-Methyltransferase.
Patra N; Ioannidis EI; Kulik HJ
PLoS One; 2016; 11(8):e0161868. PubMed ID: 27564542
[TBL] [Abstract][Full Text] [Related]
8. The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson's Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On.
Männistö PT; Keränen T; Reinikainen KJ; Hanttu A; Pollesello P
Neurol Ther; 2024 May; ():. PubMed ID: 38809484
[TBL] [Abstract][Full Text] [Related]
9. Molecular Dynamic Simulation Reveals Structure Differences in
Mayanja R; Kintu C; Diabate O; Soremekun O; Oluwagbemi OO; Wele M; Kalyesubula R; Jjingo D; Chikowore T; Fatumo S
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011371
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
Kaakkola S
Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
[TBL] [Abstract][Full Text] [Related]
12. Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-[(2,4-Dichlorophenyl)methyl]-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach.
Subair TI; Akawa OB; Soremekun OS; Olotu FA; Soliman MES
Chem Biodivers; 2021 Sep; 18(9):e2100204. PubMed ID: 34252268
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
14. Prospecting for new catechol-
da Silva IR; Parise MR; Pereira M; da Silva RA
J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
[TBL] [Abstract][Full Text] [Related]
15. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
